Wedbush: Legal Battle Between Musk and Altman May Become a Battlefield

金十2026/04/27 14:52

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Golden Ten Data reported on April 27 that Wedbush analysts stated in a report that the legal battle between xAI founder Elon Musk and OpenAI CEO Sam Altman is not expected to have a profound negative impact on OpenAI, but could escalate into a brawl. The analysts anticipate that Altman will emerge from court “with scrapes and bruises” rather than facing any genuine threat to his CEO position. Meanwhile, both parties have already engaged in public confrontations on social media, and analysts expect that “there will be a lot of scandals and attacks in court.” The analysts pointed out that, with OpenAI expected to announce its IPO later this year, the overall impact of this lawsuit could still become a challenging issue for the company.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.

智通财经•2026/11/06 08:27

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56